eXoZymes Inc. Closes $5.95 Million Public Offering and Over-Allotment Exercise

On June 17, 2026, eXoZymes Inc. (NASDAQ: EXOZ) announced the closing of a firm commitment underwritten public offering, including the partial exercise of an over-allotment option. The offering consisted of 330,575 units, where each unit comprised two shares of common stock and one warrant to purchase an additional share. The units were priced at $18.00 ($8.99 per share and $0.02 per warrant). Total gross proceeds from the offering reached approximately $5.95 million before underwriting discounts and commissions. The warrants have an exercise price of $11.24 per share, becoming exercisable one year from issuance and expiring after five years. Notably, the warrant exercise price includes a reset provision to $0.001 if the company issues securities at a lower price before June 5, 2027. eXoZymes intends to utilize the net proceeds to advance the development and commercialization of N-trans-caffeoyltyramine (NCT), fund additional R&D activities, and support general corporate purposes. MDB Capital served as the sole book-running manager for the transaction.